NCT02136134
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02136134
Title Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | SWE | POL | NLD | HUN | ESP | DEU | CZE | BRA | AUS

Facility Status City State Zip Country Details
Birmingham Alabama United States Details
Los Angeles California United States Details
Stamford Connecticut United States Details
Jacksonville Florida United States Details
Atlanta Georgia United States Details
Niles Illinois United States Details
Topeka Kansas United States Details
Westwood Kansas United States Details
Marrero Louisiana United States Details
Boston Massachusetts United States Details
Lansing Michigan United States Details
New York New York United States Details
Chapel Hill North Carolina United States Details
Portland Oregon United States Details
Philadelphia Pennsylvania United States Details
Providence Rhode Island United States Details
Seattle Washington United States Details
Adelaide Australia Details
Concord Australia Details
Fitzroy Australia Details
Hobart Australia Details
Melbourne Australia Details
Nedlands Australia Details
Woodville South Australia Details
Barretos Brazil Details
Porto Alegre Brazil Details
Salvador Brazil Details
São Paulo Brazil Details
Brno Czechia Details
Hradec Králové Czechia Details
Ostrava-Poruba Czechia Details
Prague Czechia Details
Bamberg Germany Details
Berlin Germany Details
Düsseldorf Germany Details
Freiburg im Breisgau Germany Details
Göttingen Germany Details
Hamburg Germany Details
Mainz Germany Details
München Germany Details
Stuttgart Germany Details
Tübingen Germany Details
Ulm Germany Details
Würzburg Germany Details
Budapest Hungary Details
Debrecen Hungary Details
Győr Hungary Details
Pécs Hungary Details
Veszprém Hungary Details
Huixquilucan Mexico Details
Monterrey Mexico Details
Alkmaar Netherlands Details
Amersfoort Netherlands Details
Dordrecht Netherlands Details
Groningen Netherlands Details
Leiden Netherlands Details
Maastricht Netherlands Details
Nijmegen Netherlands Details
The Hague Netherlands Details
Chorzów Poland Details
Katowice Poland Details
Krakow Poland Details
Poznan Poland Details
Warsaw Poland Details
Krasnodar Russia Details
Moscow Russia Details
Nizhny Novgorod Russia Details
Penza Russia Details
Pyatigorsk Russia Details
Ryazan Russia Details
Samara Russia Details
Sochi Russia Details
Syktyvkar Russia Details
Busan South Korea Details
Hwasun South Korea Details
Seoul South Korea Details
Suwon South Korea Details
Ulsan South Korea Details
Madrid Spain Details
Salamanca Spain Details
San Sebastián de los Reyes Spain Details
Toledo Spain Details
Valencia Spain Details
Linköping Sweden Details
Luleå Sweden Details
Lund Sweden Details
Örebro Sweden Details
Sundsvall Sweden Details
Umeå Sweden Details
Uppsala Sweden Details
Västerås Sweden Details
Ankara Turkey (Türkiye) Details
Istanbul Turkey (Türkiye) Details
Izmir Turkey (Türkiye) Details
Kayseri Turkey (Türkiye) Details
Kocaeli Turkey (Türkiye) Details
Malatya Turkey (Türkiye) Details
Cherkasy Ukraine Details
Dnipro Ukraine Details
Ivano-Frankivsk Ukraine Details
Kiev Ukraine Details
Lviv Ukraine Details
Poltava Ukraine Details
Vinnitsa Ukraine Details
Zaporizhzhya Ukraine Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field